UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prospective analysis of satisfaction and usability of closed-loop Diabeloop DBLHU treatment in patients with highly unstable type 1 diabetes

Acta diabetologica, 2021-12, Vol.58 (12), p.1709-1711

2021

Volltextzugriff (PDF)

Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial

The Lancet. Digital health, 2022-03, Vol.4 (3), p.e158-e168

2022

Volltextzugriff (PDF)

End-to-end offline reinforcement learning for glycemia control

Artificial intelligence in medicine, 2024-08, Vol.154, p.102920, Article 102920

2024

Volltextzugriff (PDF)

Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

Diabetes care, 2021-03, Vol.44 (3), p.844-846

2021

Volltextzugriff (PDF)

Short course corticosteroid treatment and closed-loop insulin delivery system: The experience of the DBLG1 pre-launch

Diabetes & metabolism, 2022-07, Vol.48 (4), p.101294-101294, Article 101294

2022

Volltextzugriff (PDF)

Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

Diabetes care, 2021-03, Vol.44 (3), p.844-846

2021

Volltextzugriff (PDF)

701-P: Time Features Improve Glucose Prediction

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

786-P: Importance of Data Distribution on Deep Learning Model for Glucose Prediction

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

Hybrid Closed-Loop Control with Ultrarapid Lispro Compared with Standard Insulin Aspart and Faster Insulin Aspart: An In Silico Study

Journal of diabetes science and technology, 2023-01, Vol.17 (1), p.176-185

2023

Volltextzugriff (PDF)

Customization of home closed-loop insulin delivery in adult patients with type 1 diabetes, assisted with structured remote monitoring: the pilot WP7 Diabeloop study

Acta diabetologica, 2018-06, Vol.55 (6), p.549-556

2018

Volltextzugriff (PDF)

278-OR: Impact of a Parameter Change in DBLG1 System

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

96-LB: Diabeloop Closed-Loop System Allows Patients with Type 1 Diabetes (T1D) to Significantly Improve Their Glycemic Control in Real-Life Situation, without Serious Adverse Events: A 6-Month Follow-Up

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

697-P: Insulin Pump Interoperability of the Diabeloop DBLG1 System

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Hybrid Closed-Loop Control with Ultrarapid Lispro Compared with Standard Insulin Aspart and Faster Insulin Aspart: An In Silico Study

Journal of diabetes science and technology, 2021-10, Vol.17 (1), p.176-185

2021

Volltextzugriff (PDF)

Efficacy of the Diabeloop closed‐loop system to improve glycaemic control in patients with type 1 diabetes exposed to gastronomic dinners or to sustained physical exercise

Diabetes, obesity & metabolism, 2020-03, Vol.22 (3), p.324-334

2020

Volltextzugriff (PDF)

Prospective analysis of satisfaction and usability of closed-loop Diabeloop DBLHU treatment in patients with highly unstable type 1 diabetes

Acta diabetologica, 2021-07, Vol.58 (12), p.1709-1711

2021

Volltextzugriff (PDF)

No more hypoglycaemia on days with physical activity and unrestricted diet when using a closed‐loop system for 12 weeks: A post hoc secondary analysis of the multicentre, randomized controlled Diabeloop WP7 trial

Diabetes, obesity & metabolism, 2021-09, Vol.23 (9), p.2170-2176

2021

Volltextzugriff (PDF)

No more hypoglycaemia on days with physical activity and unrestricted diet when using a closed‐loop system for 12weeks: A post hoc secondary analysis of the multicentre, randomized controlled Diabeloop WP7 trial

Diabetes, obesity & metabolism, 2021-09, Vol.23 (9), p.2170-2176

2021

Volltextzugriff (PDF)

Efficacy of Diabeloop closed‐loop to improve glycaemic control in patients with type 1 diabetes exposed to copious dinners or to sustained physical exercise

Diabetes, obesity & metabolism, 2019-10

2019

Volltextzugriff (PDF)

Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial

The Lancet. Digital health, 2022-03, Vol.4 (3), p.e158-e168

2022

Volltextzugriff (PDF)

CO-52 - La boucle fermée Diabeloop fait mieux que le traitement conventionnel du patient diabétique de type 1, en termes de contrôle glycémique pendant 72h, en situation d’activités physiques intenses, de repas gastronomiques ou de repos chez les DT1

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A21-A21

2017

Volltextzugriff (PDF)

La boucle fermée Diabeloop fait mieux que le traitement conventionnel du patient diabétique de type 1, en termes de contrôle glycémique pendant 72h avec des diners gastronomiques : essai croisé, randomisé en ouvert

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A49

2017

Volltextzugriff (PDF)

CAD-33 - La boucle fermée Diabeloop fait mieux que le traitement conventionnel du patient diabétique de type 1, en termes de contrôle glycémique pendant 72h avec des activités physiques intenses : essai croisé, randomisé en ouvert

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A48-A49

2017

Volltextzugriff (PDF)

CAD-34 - La boucle fermée Diabeloop fait mieux que le traitement conventionnel du patient diabétique de type 1, en termes de contrôle glycémique pendant 72h avec des diners gastronomiques : essai croisé, randomisé en ouvert

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A49-A49

2017

Volltextzugriff (PDF)

La boucle fermée Diabeloop fait mieux que le traitement conventionnel du patient diabétique de type 1, en termes de contrôle glycémique pendant 72h avec des activités physiques intenses : essai croisé, randomisé en ouvert

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A48-A49

2017

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(28)
Tagungsberichte
(1)

Sprache

Englisch
(29)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences
(13)
Science & Technology
(10)
Life Sciences & Biomedicine
(9)
Diabetes
(8)
Endocrinology & Metabolism
(7)
Diabetes Mellitus
(6)
Hypoglycemia
(6)
Diabetes Mellitus, Type 1 - Drug Therapy
(5)
Humans
(5)
Insulin
(5)
Insulin Infusion Systems
(5)
Blood Glucose
(4)
Clinical Trials
(4)
Glucose
(4)
Glucose Monitoring
(4)
Hyperglycemia
(4)
Hypoglycemic Agents - Therapeutic Use
(4)
Insulin - Therapeutic Use
(4)
Type 1 Diabetes
(4)
Artificial Pancreas
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prospective analysis of satisfaction and usability of closed-loop Diabeloop DBLHU treatment in patients with highly unstable type 1 diabetes

Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial

End-to-end offline reinforcement learning for glycemia control

Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

Short course corticosteroid treatment and closed-loop insulin delivery system: The experience of the DBLG1 pre-launch

Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

701-P: Time Features Improve Glucose Prediction

786-P: Importance of Data Distribution on Deep Learning Model for Glucose Prediction

Hybrid Closed-Loop Control with Ultrarapid Lispro Compared with Standard Insulin Aspart and Faster Insulin Aspart: An In Silico Study

Customization of home closed-loop insulin delivery in adult patients with type 1 diabetes, assisted with structured remote monitoring: the pilot WP7 Diabeloop study

278-OR: Impact of a Parameter Change in DBLG1 System

96-LB: Diabeloop Closed-Loop System Allows Patients with Type 1 Diabetes (T1D) to Significantly Improve Their Glycemic Control in Real-Life Situation, without Serious Adverse Events: A 6-Month Follow-Up

697-P: Insulin Pump Interoperability of the Diabeloop DBLG1 System

Hybrid Closed-Loop Control with Ultrarapid Lispro Compared with Standard Insulin Aspart and Faster Insulin Aspart: An In Silico Study

Efficacy of the Diabeloop closed‐loop system to improve glycaemic control in patients with type 1 diabetes exposed to gastronomic dinners or to sustained physical exercise

Prospective analysis of satisfaction and usability of closed-loop Diabeloop DBLHU treatment in patients with highly unstable type 1 diabetes

No more hypoglycaemia on days with physical activity and unrestricted diet when using a closed‐loop system for 12 weeks: A post hoc secondary analysis of the multicentre, randomized controlled Diabeloop WP7 trial

No more hypoglycaemia on days with physical activity and unrestricted diet when using a closed‐loop system for 12weeks: A post hoc secondary analysis of the multicentre, randomized controlled Diabeloop WP7 trial

Efficacy of Diabeloop closed‐loop to improve glycaemic control in patients with type 1 diabetes exposed to copious dinners or to sustained physical exercise

Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trial

CO-52 - La boucle fermée Diabeloop fait mieux que le traitement conventionnel du patient diabétique de type 1, en termes de contrôle glycémique pendant 72h, en situation d’activités physiques intenses, de repas gastronomiques ou de repos chez les DT1

La boucle fermée Diabeloop fait mieux que le traitement conventionnel du patient diabétique de type 1, en termes de contrôle glycémique pendant 72h avec des diners gastronomiques : essai croisé, randomisé en ouvert

CAD-33 - La boucle fermée Diabeloop fait mieux que le traitement conventionnel du patient diabétique de type 1, en termes de contrôle glycémique pendant 72h avec des activités physiques intenses : essai croisé, randomisé en ouvert

CAD-34 - La boucle fermée Diabeloop fait mieux que le traitement conventionnel du patient diabétique de type 1, en termes de contrôle glycémique pendant 72h avec des diners gastronomiques : essai croisé, randomisé en ouvert

La boucle fermée Diabeloop fait mieux que le traitement conventionnel du patient diabétique de type 1, en termes de contrôle glycémique pendant 72h avec des activités physiques intenses : essai croisé, randomisé en ouvert

Suchergebnisse filtern